Quarterly ResultMay 7, 2026, 08:18 AM
Prime Medicine Reports Q1 Net Loss $(49.1M); Going Concern Doubt
AI Summary
Prime Medicine reported a net loss of $49.1 million for the first quarter of 2026, an improvement from $51.9 million in the prior year. However, the company's management has concluded that substantial doubt exists about its ability to continue as a going concern for the next 12 months, citing dependence on obtaining additional financing. As of March 31, 2026, the company held $135.5 million in cash, cash equivalents, and short-term investments, with an accumulated deficit of $937.5 million.
Key Highlights
- Management identified substantial doubt about Prime Medicine's ability to continue as a going concern for 12 months.
- Net loss was $(49.1) million for Q1 2026, an improvement from $(51.9) million in Q1 2025.
- Net loss per share was $(0.28) for Q1 2026, compared to $(0.40) in Q1 2025.
- Collaboration revenue decreased to $0.86 million in Q1 2026 from $1.45 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $135.5 million as of March 31, 2026.
- Accumulated deficit reached $937.5 million as of March 31, 2026.
- Research and development expenses decreased to $34.1 million in Q1 2026 from $40.6 million in Q1 2025.
- General and administrative expenses increased to $17.4 million in Q1 2026 from $13.3 million in Q1 2025.